SEC Filing Summary — Form 10-Q
Registrant: Diffusion Pharmaceuticals Inc. The request metadata names Cervomed Inc., but the supplied filing identifies Diffusion Pharmaceuticals as the registrant.
Reporting period: Quarter ended March 31, 2017; unaudited consolidated results compared with the three months ended March 31, 2016.
Business context
Diffusion is a clinical-stage biotechnology company with no product revenue. Its lead candidate, trans sodium crocetinate (TSC), is intended to improve tumor oxygenation and enhance standard cancer treatments. The company reported orphan-drug designations for glioblastoma and metastatic brain cancer.
Financial results and position
| Metric | Q1 2017 | Q1 2016 / prior date |
|---|---|---|
| Revenue | No product-sales revenue | No product-sales revenue |
| Research and development expense | $1.01 million | $2.35 million |
| General and administrative expense | $1.55 million | $3.86 million |
| Loss from operations | $2.57 million | $6.22 million |
| Net loss | $28.64 million | $6.22 million |
| Net loss attributable to common stockholders | $28.70 million | $6.22 million |
| Basic and diluted loss per share | $2.78 | $0.62 |
| Cash used in operating activities | $3.42 million | $4.63 million |
| Cash and cash equivalents | $12.21 million at March 31, 2017 | $1.55 million at December 31, 2016 |
The company reported a $31.0 million working-capital deficit and an $88.8 million accumulated deficit. Total liabilities were $55.46 million, including a $48.15 million warrant liability and $2.43 million principal of convertible debt ($1.88 million due September 2017 and $0.55 million due June 2018). Stockholders’ equity was a deficit of $19.12 million. No operating margin is meaningful because the company had no revenue.
Material changes and unusual items
- In March, the company completed a private placement of 12,376,329 Series A preferred-stock units with warrants. It reported approximately $22.1 million in aggregate net proceeds; $8.3 million was received on April 3, after quarter-end. The cash-flow statement records $14.3 million of proceeds received during the quarter, net of offering costs.
- Q1 net loss includes $12.92 million from an increase in the fair value of warrant liabilities, $10.23 million of warrant-related expense, and $2.87 million of other financing expenses. These financing-related items explain most of the year-over-year increase in net loss; the warrant liability is remeasured each reporting period.
- Operating expenses declined from Q1 2016. Management attributed the R&D decrease mainly to lower pancreatic-cancer program and animal-toxicology spending, and the G&A decrease primarily to $2.4 million less in reverse-merger costs. The prior-year comparison includes merger-related activity and is not fully comparable.
- Series A preferred stock carries an 8% cumulative dividend payable in common shares, conversion rights, and a liquidation preference. The related warrants are liability-classified; potential securities were excluded from diluted loss per share as anti-dilutive.
Outlook, risks and contingencies
- Management estimated that cash at quarter-end plus the April subscription proceeds would fund planned operations through March 2018. It expects substantial future losses and increased expenses as clinical development advances; additional funding will be needed to conduct all planned programs.
- The company planned, subject to FDA agreement on the protocol, to initiate a Phase III TSC study in newly diagnosed, inoperable glioblastoma patients by the end of 2017. A pancreatic-cancer Phase II study and a brain-metastases study were contingent on funding or partnering. A Phase III start within the next twelve months was also stated as an expectation.
- Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing recurring losses and dependence on future financing. Failure to raise capital could force delays, reductions, partnerships involving surrendered rights, a strategic transaction, or cessation of operations.
- The warrant accounting reduced reported stockholders’ equity below an applicable Nasdaq continued-listing requirement. The company was exploring alternatives to regain compliance; delisting could impair trading and future capital raising.
- A former CEO’s arbitration claim seeks damages in an undetermined amount. The company said it considers the matter without merit, but could not estimate a possible loss or its effect.
- A new office and laboratory lease runs from May 2017 through April 2022, with total minimum payments of approximately $575,000. The filing reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Key facts for investors to verify
- Whether the April 3 receipt of $8.3 million occurred as disclosed and how the private-placement proceeds affect the actual cash runway.
- The timing, protocol, funding, and regulatory status of the planned glioblastoma Phase III trial and other TSC studies.
- Nasdaq continued-listing compliance and any remedial financing or capital-structure actions.
- The valuation assumptions and subsequent fair-value changes for the $48.15 million warrant liability, and the resulting potential dilution and preferred-stock rights.
- Developments in the former CEO arbitration and the company’s ability to obtain additional financing before its stated runway ends.